Novartis’ LUTATHERA for GEP-NET Treatment: Ray ...

Biochips have emerged as indispensable tools in the healthcare sector, revolutionizing the way diseases are diagnosed, monitored, and treated. These miniature laboratories on a chip offer unparalleled efficiency, sensitivity, and speed in analyzing biological samples, making them invaluable in various medical appli...

ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous sy...

Glaucoma, often dubbed as the “silent thief of sight,” poses a significant challenge in the domain of ophthalmology. Glaucoma treatment has made significant strides, yet several unmet needs persist, posing challenges to effective management and vision preservation. By prioritizing early detection, embracing persona...

The Medical Tourism market has emerged as a dynamic sector in recent years, experiencing significant evolution driven by a myriad of factors. Traditionally, Medical Tourism referred to the practice of traveling abroad for medical treatment, often sought due to cost considerations, access to advanced technologies, o...

After Johnson & Johnson reversed its decision last year regarding the acquisition of Tryvio (aprocitentan) in 2017, the original manufacturer of the hypertension treatment drug, Idorsia Pharmaceuticals has successfully guided the drug through the FDA approval process. The company stated that Tryvio, its endo...

Fifteen years after its first FDA approval for treating schizophrenia with Fanapt (iloperidone), Vanda Pharmaceuticals has achieved another success. Fanapt is a type of antipsychotic medication that deviates from the usual and has been administered to individuals with schizophrenia for their immediate treatment fol...